# Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

> **NCT04962958** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 30 (estimated)

## Conditions studied

- Carcinoma
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Digestive System Neoplasms
- Antineoplastic Agents
- Donafenib
- Fluorouracil
- Oxaliplatin
- Antimetabolites

## Interventions

- **PROCEDURE:** Hepatic arterial infusion chemotherapy
- **DRUG:** Folfox Protocol
- **DRUG:** Donafenib

## Key facts

- **NCT ID:** NCT04962958
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2024-03
- **Final completion:** 2024-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04962958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04962958, "Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04962958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*